arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Lyell Immunopharma, Inc.

LYEL
$14.94 ▼ -0.53 (-3.43%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
28 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Lyell Immunopharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $349.1M
Dividend Yield —
Revenue Growth -50.0% ↗
Op. Margin None
ROIC -16.0% ↘
FCF / Share $-1.46 ↗
Trailing P/E —
Price / Book 1.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.00K
↓ -50.0% —
Net Income Profit after all expenses
$-44.76M
↓ -4.9% —
Operating Margin Operating profit as % of sales
-30.6%
↑ +70.7% —
FCF / Share Free cash flow per share
$-1.46
↑ +17.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
8
Cash Quality ↓
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 28 quarters